Brian Michael Varisco
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Brian Michael Varisco has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
Rashika Joshi
Cincinnati Children’s Hospital Medical Center
21 shared publicationsNoah J. Smith
University of Cincinnati Cincinnati, Ohio
7 shared publicationsQiang Fan
Critical Care Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
7 shared publicationsAndrew J. Devine
Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, United States
5 shared publications- Hector R. Wong
Division of Critical Care Medicine, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
5 shared publications Sheng Liu
Division of Critical Care Medicine, Division of Developmental Biology, and Division of Pulmonary Biology, Department of Clinical Engineering, and Biomedical Research Internship for Minority Students Program, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA; and Ohio State University College of Veterinary Medicine, Columbus, Ohio, USA
4 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Lung ultrasound feature tracking to quantify regional lung strain in mechanically ventilated pigs
In patients requiring respiratory support, clinicians rely on physical exam, radiologic, laboratory, and ventilator-derived measures for the provision of sufficient support while minimizing ventilator and "work of breathing" induced lung injury. Point of care lung ultrasound (LUS) is a widely available tool in hospital and clinic environments. To date, LUS has not been used to evaluate lung strain. We collected LUS images in four anesthetized, neuromuscularly blocked, and mechanically ventilated pigs being used for another experiment. A feature tracking tool was developed which tracked echo-bright lung structures in 8-10 s clips obtained in triplicate of the right and left, upper and lower lung fields using tidal volumes of 4, 6, 8, 10, and 12 mL/kg. Pleural lines were manually drawn and a program for quantifying lung strain developed with assistance from Anthropic Claude Artificial Intelligence tool. Structures were identified in inspiratory and expiratory frames and tracked bidirectionally with median strain per clip used for calculations. Triplicate measures of lung ultrasound images in four pigs had a median coefficients of variation of 35% (23-47% IQR) and linear modeling of strain with tidal volumes of 4-12 mL/kg showed positive correlation with R2 value ranging from 0.89 to 0.97. Strain measurements were similar after bronchial administration of 1.5 M hydrochloric acid. These findings demonstrate the feasibility of quantifying regional lung strain using LUS and support its further development as a tool for respiratory support management.
- 1 July 2026
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Open AccessLung ultrasound feature tracking to quantify regional lung strain in mechanically ventilated pigs
In patients requiring respiratory support, clinicians rely on physical exam, radiologic, laboratory, and ventilator-derived measures for the provision of sufficient support while minimizing ventilator and "work of breathing" induced lung injury. Point of care lung ultrasound (LUS) is a widely available tool in hospital and clinic environments. To date, LUS has not been used to evaluate lung strain. We collected LUS images in four anesthetized, neuromuscularly blocked, and mechanically ventilated pigs being used for another experiment. A feature tracking tool was developed which tracked echo-bright lung structures in 8-10 s clips obtained in triplicate of the right and left, upper and lower lung fields using tidal volumes of 4, 6, 8, 10, and 12 mL/kg. Pleural lines were manually drawn and a program for quantifying lung strain developed with assistance from Anthropic Claude Artificial Intelligence tool. Structures were identified in inspiratory and expiratory frames and tracked bidirectionally with median strain per clip used for calculations. Triplicate measures of lung ultrasound images in four pigs had a median coefficients of variation of 35% (23-47% IQR) and linear modeling of strain with tidal volumes of 4-12 mL/kg showed positive correlation with R2 value ranging from 0.89 to 0.97. Strain measurements were similar after bronchial administration of 1.5 M hydrochloric acid. These findings demonstrate the feasibility of quantifying regional lung strain using LUS and support its further development as a tool for respiratory support management.
- Open Access
Lung Ultrasound Feature Tracking to Quantify Regional Lung Strain in Mechanically Ventilated Pigs
Background: In patients requiring respiratory support, clinicians rely on physical exam, radiologic, laboratory, and ventilator-derived measures for the provision of sufficient support while minimizing ventilator and “work of breathing” induced lung injury. Point of care lung ultrasound (LUS) is a widely available tool in hospital and clinic environments. To date, LUS has not been used to evaluate lung strain. Methods: We collected LUS images in four anesthetized, neuromuscularly blocked, and mechanically ventilated pigs being used for another experiment. A feature tracking tool was developed which tracked echo-bright lung structures in ten second clips obtained in triplicate of the right and left, upper and lower lung fields using tidal volumes of 4, 6, 8, 10, and 12 mL/kg. Pleural lines were manually drawn and a program for quantifying lung strain developed with assistance from Anthropic Claude Artificial Intelligence tool. Structures were identified in inspiratory and expiratory frames and tracked bidirectionally with median strain per frame used for calculations. Results: Triplicate measures of lung ultrasound images in four pigs had a median coefficients of variation of 35% (23-47% IQR) and linear modeling of strain with tidal volumes of 4-12 mL/kg showed positive correlation with R 2 value ranging from 0.89 to 0.97. Strain measurements were similar after bronchial administration of 1.5M hydrochloric acid. Conclusions: Regional lung strain quantification using LUS is a viable and potentially useful tool for respiratory support management.
Open AccessLung Ultrasound Feature Tracking to Quantify Regional Lung Strain in Mechanically Ventilated Pigs
Background: In patients requiring respiratory support, clinicians rely on physical exam, radiologic, laboratory, and ventilator-derived measures for the provision of sufficient support while minimizing ventilator and “work of breathing” induced lung injury. Point of care lung ultrasound (LUS) is a widely available tool in hospital and clinic environments. To date, LUS has not been used to evaluate lung strain. Methods: We collected LUS images in four anesthetized, neuromuscularly blocked, and mechanically ventilated pigs being used for another experiment. A feature tracking tool was developed which tracked echo-bright lung structures in ten second clips obtained in triplicate of the right and left, upper and lower lung fields using tidal volumes of 4, 6, 8, 10, and 12 mL/kg. Pleural lines were manually drawn and a program for quantifying lung strain developed with assistance from Anthropic Claude Artificial Intelligence tool. Structures were identified in inspiratory and expiratory frames and tracked bidirectionally with median strain per frame used for calculations. Results: Triplicate measures of lung ultrasound images in four pigs had a median coefficients of variation of 35% (23-47% IQR) and linear modeling of strain with tidal volumes of 4-12 mL/kg showed positive correlation with R 2 value ranging from 0.89 to 0.97. Strain measurements were similar after bronchial administration of 1.5M hydrochloric acid. Conclusions: Regional lung strain quantification using LUS is a viable and potentially useful tool for respiratory support management.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 329 (6) , L749-L755
Novel murine partial tracheal occlusion model with altered respiratory dynamics
Lung diseases often involve both the conducting airways and the lung parenchyma, but we do not have tools to determine the mechanisms by which one affects the other. We developed a mouse partial tracheal occlusion model that increases the pressure required to generate a breath and also a novel way to measure this pressure. We can now test different hypotheses about how lung strain causes pathological lung remodeling.
- 1 December 2025
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 329 (6) , L749-L755
Novel murine partial tracheal occlusion model with altered respiratory dynamics
Lung diseases often involve both the conducting airways and the lung parenchyma, but we do not have tools to determine the mechanisms by which one affects the other. We developed a mouse partial tracheal occlusion model that increases the pressure required to generate a breath and also a novel way to measure this pressure. We can now test different hypotheses about how lung strain causes pathological lung remodeling.
- Open Access
- 1 August 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (8) , 1101-1114
Research Priorities for Noninvasive Sampling of the Lower Respiratory Tract During Acute Respiratory Failure: An Official American Thoracic Society Workshop Report
Research using lower respiratory tract (LRT) sampling may lead to improved understanding and management of patients with acute respiratory failure (ARF). Research bronchoscopy is a valuable tool for sampling the LRT during ARF. However, bronchoscopy may be limited by challenges with repeated sampling, the inability to sample the most severely ill patients, and increased resource utilization. “Noninvasive” sampling strategies, such as nonbronchoscopic bronchoalveolar lavage, endotracheal aspirate collection, and heat moisture exchange filter fluid collection, may expand the opportunity to collect LRT samples for research. Upper respiratory tract and sputum sampling may enable sampling in nonintubated patients with ARF, for whom there is no direct noninvasive access to the LRT. We convened a workshop with 32 experts from diverse continents, scientific backgrounds, and healthcare professions, all with experience in clinical or research practice during ARF. The Workshop goals were to review existing noninvasive sampling methods, evaluate their respective potential benefits and limitations, and identify future research priorities aimed at improving standardization and integration of these approaches into practice. Findings were generated by review of literature, expert presentations, meeting discussions, and electronic surveys using a modified Delphi approach. Participants agreed that each sampling method provides biologically meaningful data during ARF while also acknowledging that each method has benefits and limitations. Various potential advantages to noninvasive methods include reduced cost, enhanced speed, and ease of adoption compared with standard fiberoptic bronchoscopy. Despite the potential advantages, rigorous head-to-head comparisons between noninvasive methods and/or standard bronchoscopy are limited, which is a priority for future research. Additional research priorities include examination of the feasibility and benefit of serial sampling of the LRT and investigation of how LRT biomarkers are related to lung pathophysiology and patient-centered clinical outcomes during ARF. This Workshop Report provides guidance for investigators to integrate LRT sampling into their research and highlights key priorities, such as rigorous head-to-head comparison of sampling methods for research, to improve the standardization of noninvasive sampling methods and use of LRT sampling in research and clinical practice.
- 1 August 2025
- Published by Oxford University Press (OUP) in Annals of the American Thoracic Society
- Vol. 22 (8) , 1101-1114
Open AccessResearch Priorities for Noninvasive Sampling of the Lower Respiratory Tract During Acute Respiratory Failure: An Official American Thoracic Society Workshop Report
Research using lower respiratory tract (LRT) sampling may lead to improved understanding and management of patients with acute respiratory failure (ARF). Research bronchoscopy is a valuable tool for sampling the LRT during ARF. However, bronchoscopy may be limited by challenges with repeated sampling, the inability to sample the most severely ill patients, and increased resource utilization. “Noninvasive” sampling strategies, such as nonbronchoscopic bronchoalveolar lavage, endotracheal aspirate collection, and heat moisture exchange filter fluid collection, may expand the opportunity to collect LRT samples for research. Upper respiratory tract and sputum sampling may enable sampling in nonintubated patients with ARF, for whom there is no direct noninvasive access to the LRT. We convened a workshop with 32 experts from diverse continents, scientific backgrounds, and healthcare professions, all with experience in clinical or research practice during ARF. The Workshop goals were to review existing noninvasive sampling methods, evaluate their respective potential benefits and limitations, and identify future research priorities aimed at improving standardization and integration of these approaches into practice. Findings were generated by review of literature, expert presentations, meeting discussions, and electronic surveys using a modified Delphi approach. Participants agreed that each sampling method provides biologically meaningful data during ARF while also acknowledging that each method has benefits and limitations. Various potential advantages to noninvasive methods include reduced cost, enhanced speed, and ease of adoption compared with standard fiberoptic bronchoscopy. Despite the potential advantages, rigorous head-to-head comparisons between noninvasive methods and/or standard bronchoscopy are limited, which is a priority for future research. Additional research priorities include examination of the feasibility and benefit of serial sampling of the LRT and investigation of how LRT biomarkers are related to lung pathophysiology and patient-centered clinical outcomes during ARF. This Workshop Report provides guidance for investigators to integrate LRT sampling into their research and highlights key priorities, such as rigorous head-to-head comparison of sampling methods for research, to improve the standardization of noninvasive sampling methods and use of LRT sampling in research and clinical practice.
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (2) , 325-327
Targeting CELA1 to Improve Septation in the Mouse Hyperoxia Model of Impaired Alveolar Development
- 1 August 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory Cell and Molecular Biology
- Vol. 73 (2) , 325-327
Targeting CELA1 to Improve Septation in the Mouse Hyperoxia Model of Impaired Alveolar Development
- 1 January 2025
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 12 (1) , 12-22
KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1-deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in porcine pancreatic elastase (PPE) and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, spleen, and bone marrow. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. By histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT-/- mice treated with 0.2 units of PPE. In this injury model, AAT-/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 & AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.
- 1 January 2025
- Published by COPD Foundation in Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation
- Vol. 12 (1) , 12-22
KF4 Anti-Chymotrypsin-like Elastase 1 Antibody and Purified Alpha-1 Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine Alpha-1 Antitrypsin Deficiency
Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1-deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in porcine pancreatic elastase (PPE) and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, spleen, and bone marrow. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. By histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT-/- mice treated with 0.2 units of PPE. In this injury model, AAT-/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 & AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.
- Open Access
- 11 December 2024
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (1)
Derivation and Validation of a Clinical and Endothelial Biomarker Risk Model to Predict Persistent Pediatric Sepsis-Associated Acute Respiratory Dysfunction
- 11 December 2024
- Published by Elsevier in CHEST Critical Care
- Vol. 3 (1)
Open AccessDerivation and Validation of a Clinical and Endothelial Biomarker Risk Model to Predict Persistent Pediatric Sepsis-Associated Acute Respiratory Dysfunction
- Open Access
Inhibition of CELA1 Improves Septation in the Mouse Hyperoxia Model of Impaired Alveolar Development
A key feature of bronchopulmonary dysplasia (BPD) is impaired alveolar septation. In later live, BPD survivors are more susceptible to childhood respiratory problems and have reduced respiratory function as adults. Chymotrypsin-like elastase 1 (CELA1) is a serine protease expressed in AT2 cells that mediates emphysema progression in adult mouse models. CELA1 binds and cleaves tropoelastin in response to strain. Its expression is developmentally regulated. Using the mouse hyperoxia model of impaired alveolar development we hypothesized a role for CELA1 in impaired alveolar development (IAD). In C57BL6 mouse pup lungs exposed to 80% oxygen for 14 days Cela1 mRNA increased 1.9-fold (pCela1 mRNA in AT2 cells, alveolar macrophages and interstitial macrophages. The fraction of cells with Cela1 mRNA increased with hyperoxia. By flow cytometry the only Cela1 -specific difference in immune cell populations was a 2-fold increase in lung eosinophils in room air (pCela1 -/- mice had better alveolarization with an average mean linear intercept of 80 μm compared to 111μm (p2 .
Open AccessInhibition of CELA1 Improves Septation in the Mouse Hyperoxia Model of Impaired Alveolar Development
A key feature of bronchopulmonary dysplasia (BPD) is impaired alveolar septation. In later live, BPD survivors are more susceptible to childhood respiratory problems and have reduced respiratory function as adults. Chymotrypsin-like elastase 1 (CELA1) is a serine protease expressed in AT2 cells that mediates emphysema progression in adult mouse models. CELA1 binds and cleaves tropoelastin in response to strain. Its expression is developmentally regulated. Using the mouse hyperoxia model of impaired alveolar development we hypothesized a role for CELA1 in impaired alveolar development (IAD). In C57BL6 mouse pup lungs exposed to 80% oxygen for 14 days Cela1 mRNA increased 1.9-fold (pCela1 mRNA in AT2 cells, alveolar macrophages and interstitial macrophages. The fraction of cells with Cela1 mRNA increased with hyperoxia. By flow cytometry the only Cela1 -specific difference in immune cell populations was a 2-fold increase in lung eosinophils in room air (pCela1 -/- mice had better alveolarization with an average mean linear intercept of 80 μm compared to 111μm (p2 .
- Open Access
KF4 anti-CELA1 Antibody and Purified α1-Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine α1-Antitrypsin Deficiency
Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1 -deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in PPE and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, and spleen. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. In histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT -/- mice treated with 0.2 units of PPE. In this injury model, AAT -/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 & AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.
Open AccessKF4 anti-CELA1 Antibody and Purified α1-Antitrypsin Have Similar but Not Additive Efficacy in Preventing Emphysema in Murine α1-Antitrypsin Deficiency
Alpha-1 antitrypsin (AAT) deficiency is the most common genetic cause of emphysema. Chymotrypsin-like Elastase 1 (CELA1) is a serine protease neutralized by AAT and is important in emphysema progression. Cela1 -deficiency is protective in a murine models of AAT-deficient emphysema. KF4 anti-CELA1 antibody prevented emphysema in PPE and cigarette smoke models in wild type mice. We evaluated potential toxicities of KF4 and its ability to prevent emphysema in AAT deficiency. We found Cela1 protein expression in mouse lung, pancreas, small intestine, and spleen. In toxicity studies, mice treated with KF4 25 mg/kg weekly for four weeks showed an elevation in blood urea nitrogen and slower weight gain compared to lower doses or equivalent dose IgG. In histologic grading of tissue injury of the lung, kidney, liver, and heart, there was some evidence of liver injury with KF4 25 mg/kg, but in all tissues, injury was less than in control mice subjected to cecal ligation and puncture. In efficacy studies, KF4 doses as low as 0.5 mg/kg reduced the lung elastase activity of AAT -/- mice treated with 0.2 units of PPE. In this injury model, AAT -/- mice treated with KF4 1 mg/kg weekly, human purified AAT 60 mg/kg weekly, and combined KF4 and AAT treatment had less emphysema than mice treated with IgG 1 mg/kg weekly. However, the efficacy of KF4, AAT, or KF4 & AAT was similar. While KF4 might be an alternative to AAT replacement, combined KF4 and AAT replacement does not confer additional benefit.
- 9 April 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 25 (7) , 599-608
Biomarker-Based Risk Stratification Tool in Pediatric Acute Respiratory Distress Syndrome: Single-Center, Longitudinal Validation in a 2014–2019 Cohort
OBJECTIVES: The Pediatric Acute Respiratory Distress Syndrome Biomarker Risk Model (PARDSEVERE) used age and three plasma biomarkers measured within 24 hours of pediatric acute respiratory distress syndrome (ARDS) onset to predict mortality in a pilot cohort of 152 patients. However, longitudinal performance of PARDSEVERE has not been evaluated, and it is unclear whether the risk model can be used to prognosticate after day 0. We, therefore, sought to determine the test characteristics of PARDSEVERE model and population over the first 7 days after ARDS onset. DESIGN: Secondary unplanned post hoc analysis of data from a prospective observational cohort study carried out 2014–2019. SETTING: University-affiliated PICU. PATIENTS: Mechanically ventilated children with ARDS. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Between July 2014 and December 2019, 279 patients with ARDS had plasma collected at day 0, 266 at day 3 (11 nonsurvivors, two discharged between days 0 and 3), and 207 at day 7 (27 nonsurvivors, 45 discharged between days 3 and 7). The actual prevalence of mortality on days 0, 3, and 7, was 23% (64/279), 14% (38/266), and 13% (27/207), respectively. The PARDSEVERE risk model for mortality on days 0, 3, and 7 had area under the receiver operating characteristic curve (AUROC [95% CI]) of 0.76 (0.69–0.82), 0.68 (0.60–0.76), and 0.74 (0.65–0.83), respectively. The AUROC data translate into prevalence thresholds for the PARDSEVERE model for mortality (i.e., using the sensitivity and specificity values) of 37%, 27%, and 24% on days 0, 3, and 7, respectively. Negative predictive value (NPV) was high throughout (0.87–0.90 for all three-time points). CONCLUSIONS: In this exploratory analysis of the PARDSEVERE model of mortality risk prediction in a population longitudinal series of data from days 0, 3, and 7 after ARDS diagnosis, the diagnostic performance is in the “acceptable” category. NPV was good. A major limitation is that actual mortality is far below the prevalence threshold for such testing. The model may, therefore, be more useful in cohorts with higher mortality rates (e.g., immunocompromised, other countries), and future enhancements to the model should be explored.
- 9 April 2024
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
- Vol. 25 (7) , 599-608
Biomarker-Based Risk Stratification Tool in Pediatric Acute Respiratory Distress Syndrome: Single-Center, Longitudinal Validation in a 2014–2019 Cohort
OBJECTIVES: The Pediatric Acute Respiratory Distress Syndrome Biomarker Risk Model (PARDSEVERE) used age and three plasma biomarkers measured within 24 hours of pediatric acute respiratory distress syndrome (ARDS) onset to predict mortality in a pilot cohort of 152 patients. However, longitudinal performance of PARDSEVERE has not been evaluated, and it is unclear whether the risk model can be used to prognosticate after day 0. We, therefore, sought to determine the test characteristics of PARDSEVERE model and population over the first 7 days after ARDS onset. DESIGN: Secondary unplanned post hoc analysis of data from a prospective observational cohort study carried out 2014–2019. SETTING: University-affiliated PICU. PATIENTS: Mechanically ventilated children with ARDS. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Between July 2014 and December 2019, 279 patients with ARDS had plasma collected at day 0, 266 at day 3 (11 nonsurvivors, two discharged between days 0 and 3), and 207 at day 7 (27 nonsurvivors, 45 discharged between days 3 and 7). The actual prevalence of mortality on days 0, 3, and 7, was 23% (64/279), 14% (38/266), and 13% (27/207), respectively. The PARDSEVERE risk model for mortality on days 0, 3, and 7 had area under the receiver operating characteristic curve (AUROC [95% CI]) of 0.76 (0.69–0.82), 0.68 (0.60–0.76), and 0.74 (0.65–0.83), respectively. The AUROC data translate into prevalence thresholds for the PARDSEVERE model for mortality (i.e., using the sensitivity and specificity values) of 37%, 27%, and 24% on days 0, 3, and 7, respectively. Negative predictive value (NPV) was high throughout (0.87–0.90 for all three-time points). CONCLUSIONS: In this exploratory analysis of the PARDSEVERE model of mortality risk prediction in a population longitudinal series of data from days 0, 3, and 7 after ARDS diagnosis, the diagnostic performance is in the “acceptable” category. NPV was good. A major limitation is that actual mortality is far below the prevalence threshold for such testing. The model may, therefore, be more useful in cohorts with higher mortality rates (e.g., immunocompromised, other countries), and future enhancements to the model should be explored.